Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligo
M. Larsabal(Hôpital Saint-André), Julien Sénéschal(Université de Bordeaux), Katia Boniface(Université de Bordeaux), C. Jacquemin(Centre National de la Recherche Scientifique), Jérôme Rambert(Université de Bordeaux), Alain Taı̈eb(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Denis Thiolat(Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers), S. Prey(Centre Hospitalier Universitaire de Bordeaux), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), A. Marti(Hôpital Saint-André)
Cited by 157
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k